A genetically engineered fusion epitope subunit vaccine for preventing Mycoplasma gallisepticum and its preparation method

Through genetically engineered fusion epitope subunit vaccine, the combination of recombinant proteins and adjuvants has been used to solve the problems of high production costs and poor immune effects of existing vaccines, achieving efficient and low-cost prevention of Mycoplasma chicken poison, significantly reducing breeding Economic losses of chicken farms.

CN117964782BActive Publication Date: 2024-12-03JINYU YOUBANG BIOTECHNOLOGY (JIANGSU) CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202410143733.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-01-31
Publication Date
2024-12-03
Estimated Expiration
2044-01-31

AI Technical Summary

Technical Problem

The existing Mycoplasma chicken poison vaccine has high production costs, low production efficiency, and poor immune effect, making it difficult to effectively prevent the spread of Mycoplasma chicken poison and economic losses.

Method used

Using genetically engineered fusion epitope subunit vaccine, the recombinant protein MGepitopes, which is composed of the tandem fusion of the B-cell and T-cell epitope of the Mycoplasma of Chickensis, the DLAT, pdhA and pstP proteins, was prepared by combining adjuvant vaccine, and the recombinant baculovirus expression was used. and purification technology to form a water-in-oil vaccine.

Benefits of technology

It has achieved low-cost and high-efficiency vaccine production, and has good immunization effect. It can achieve a protection rate of 90-100% if only one immunization is needed. It effectively prevents chicken poison Mycoplasma disease and reduces the vaccine and labor costs of chicken farms.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117964782B_ABST
    Figure CN117964782B_ABST
Patent Text Reader

Abstract

The invention discloses a genetically engineered fusion epitope subunit vaccine for preventing Mycoplasma gallisepticum and a preparation method thereof, and belongs to the field of veterinary biological products. The Mycoplasma gallisepticum genetically engineered fusion epitope subunit vaccine provided by the invention comprises a Mycoplasma gallisepticum fusion epitope MGepitopes recombinant protein, which is composed of a series fusion of B cell and T cell epitopes of DLAT, pdhA and pstP proteins of Mycoplasma gallisepticum. The Mycoplasma gallisepticum genetically engineered fusion epitope subunit vaccine of the invention has a good immune effect, a small immune dose, and can effectively prevent diseases caused by Mycoplasma gallisepticum. The preparation method of the invention is simple, can prepare a large amount of antigenic proteins of Mycoplasma gallisepticum, is short in time, has a high expression amount, greatly reduces the production cost, and is conducive to large-scale production.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a genetic engineering fusion epitope subunit vaccine for preventing Mycoplasma gallisepticum and a preparation method thereof, and belongs to the field of veterinary biological products. Background Art

[0002] Mycoplasma gallisepticum infection, also known as chronic respiratory disease in chickens, is a disease caused by Mycoplasma gallisepticum (MG) in chickens. The main symptoms of sick chickens are coughing, runny nose, conjunctivitis, respiratory inflammation, decreased production performance, and increased feed-to-meat ratio in fattening chickens.

[0003] Mycoplasma gallisepticum can occur all year round, especially in the cold winter and early spring, with high morbidity and low mortality. Chickens infected once carry the disease for life, which is passed down from generation to generation and has a great impact on the growth, development and production performance of poultry. The disease is also common in chicken farms in China and has become one of the important infectious diseases that endanger the poultry industry.

[0004] The main clinical symptoms of chicks infected with MG are gurgling breathing, sneezing and coughing, and mucous nasal discharge in the nasal cavity, which often blocks the nostrils and affects breathing. The conjunctiva of the eyes is flushed, tears increase, and the eyelids are swollen. In addition, sick chickens have a loss of appetite, lethargy, slow growth, and weight loss. The clinical symptoms of adult chickens infected with MG are similar to those of vegetative chickens, but are milder than those of vegetative chickens. The egg-laying rate of sick egg-laying chickens decreases, soft-shelled eggs are laid, the fertilization rate and hatching rate of breeding eggs are reduced, and the hatched chicks are often weak. Severe infections may also cause pneumonia, pericarditis, and hepatitis. When MG infects chickens, it is easy to cause secondary mixed infections of Escherichia coli, Newcastle disease virus, and infectious bronchitis virus in the chickens, leading to aggravated respiratory symptoms, serious complications, and increased mortality in the chickens, causing huge economic losses to farmers. Autopsy revealed that there was a lot of viscous liquid or catarrhal secretions in the nostril air sacs, trachea and bronchi of the chickens, edema of the tracheal wall, thickening of the air sac membrane and grayish white opaqueness in the early stage of infection, and cheesy exudates on the air sac wall in the late stage of infection. Inflammation of the oviduct was found in laying hens during autopsy, and fibrous pericarditis and perihepatitis were found when mixed with E. coli infection.

[0005] The vaccines for the prevention of Mycoplasma gallisepticum come from abroad, namely the Mycoplasma gallisepticum live vaccine (TS-11 strain) of Australian Bioresources Ltd. and the Mycoplasma gallisepticum inactivated vaccine (R strain) of Intervet USA. The production method of the vaccine for the prevention of Mycoplasma gallisepticum involved in this patent has important practical significance, with low production cost, high production efficiency and good vaccine immune effect. Summary of the invention

[0006] In order to solve the above technical problems, the purpose of the present invention is to provide a genetic engineering fusion epitope subunit vaccine for preventing Mycoplasma gallisepticum and a preparation method thereof. The vaccine composition has low production cost, high production efficiency and good immune effect.

[0007] In order to achieve the above technical objectives and the above technical effects, the present invention is implemented through the following technical solutions:

[0008] The first object of the present invention is to provide a multi-epitope fusion antigen MGepitopes, which is a recombinant protein composed of B cell and T cell epitopes of DLAT, pdhA and pstP proteins of Mycoplasma gallisepticum fused in series.

[0009] In one embodiment, the B cell epitope sequence of the DLAT protein is DGSSAPAAAPATPAFVAPTPAVTPAPTPAEAAPSGGGGGGGASVVGEVKVSNTLFGLFGDQRAASTPTPAPTPAFAPTPVPVATPLAQAVASDLNVNLHNVTPANGAKIFSSDVFASAQQSSPAASVAANDNETYKEITSIGRVIDPSYVQKLSDERVIE; the B cell epitope sequence of the pdhA protein is NGNEKGNVFDEGGGGGSSTRTNLESAVSDGGGGSTTSDDPSVY RTKQEEEEAK; the T cell epitope sequence of pdhA protein is GLWDEAKEKTMFEQIEAKISEEYDVMLQHIQTTVDDVFNFDNNKIKPTEVEETIT; the B cell epitope sequence of pstP protein is EGIEDAYLKERASDIGDGGGGSLSEADITTLKQDQQRYNESQAKLKKYLPPKAVTLD; the B cell epitope sequence of pstP protein is SANWPDEETQFNGGGGSIGGDKKLNYYQFPEEMGGGGSLKYSDSKELVNRVINLESQEEVVKKDELRDELKDEL.

[0010] In one embodiment, the amino acid sequence of the multi-epitope fusion antigen MGepitopes is shown as SEQ ID NO.1.

[0011] The second object of the present invention is to provide a gene encoding the multi-epitope fusion antigen MGepitopes.

[0012] In one embodiment, the nucleotide sequence of the gene is shown as SEQ ID NO.2.

[0013] The third object of the present invention is to provide biological materials expressing the multi-epitope fusion antigen MGepitopes.

[0014] In one embodiment, the biomaterial is any one of the following (1) to (3):

[0015] (1) a vector for expressing the gene;

[0016] (2) a host cell containing the gene or the vector described in (1);

[0017] (3) A recombinant virus containing the gene, the vector described in (1), or the host cell described in (2).

[0018] In one embodiment, the cell is a prokaryotic cell or a eukaryotic cell.

[0019] In one embodiment, the prokaryotic cell comprises Escherichia coli, and the eukaryotic cell comprises a mammalian cell, an insect cell or a yeast cell.

[0020] The fourth object of the present invention is to provide a composition comprising the multi-epitope fusion antigen MGepitopes or the gene or the biological material.

[0021] The fifth object of the present invention is to provide a genetically engineered fusion epitope subunit vaccine for preventing Mycoplasma gallisepticum, wherein the vaccine contains the multi-epitope fusion antigen MGepitopes.

[0022] In one embodiment, the total content of the multi-epitope fusion antigen MGepitopes in the subunit vaccine is 50-150 μg / mL.

[0023] The sixth object of the present invention is to provide the use of the multi-epitope fusion antigen MGepitopes or the gene or the biological material or the composition in the preparation of a drug for preventing and / or controlling Mycoplasma gallisepticum infection or Mycoplasma gallisepticum disease.

[0024] In one embodiment, the medicament comprises a subunit vaccine.

[0025] In one embodiment, the total content of the multi-epitope fusion antigen MGepitopes in the subunit vaccine is 50-150 μg / mL.

[0026] In one embodiment, the subunit vaccine further comprises an adjuvant.

[0027] In one embodiment, the adjuvant includes but is not limited to: aluminum salt adjuvant, liposome adjuvant, nanoparticle adjuvant, saponin adjuvant.

[0028] In one embodiment, the adjuvant in the subunit vaccine is a mineral oil adjuvant.

[0029] In one embodiment, the administration of the subunit vaccine includes intramuscular, intradermal or subcutaneous administration.

[0030] The seventh object of the present invention is to provide the use of the multi-epitope fusion antigen MGepitopes or the gene or the biological material or the composition in the preparation of Mycoplasma gallisepticum antibodies or Mycoplasma gallisepticum serum.

[0031] The eighth object of the present invention is to provide a method for preparing the genetically engineered fusion epitope subunit vaccine for preventing Mycoplasma gallisepticum, and the specific steps of the method are as follows:

[0032] (1) The nucleotide sequences of the genes encoding the MGepitopes proteins were respectively connected to the pFastBac I vector to obtain the recombinant plasmid MG-F;

[0033] (2) transforming the recombinant plasmid MG-F obtained in step (1) into DH10 Bac competent cells to obtain the recombinant bacmid rBacmid-MG-F;

[0034] (3) transfecting insect cells with the recombinant bacmid rBacmid-MG-F obtained in step (2) to obtain recombinant baculovirus rMG-F;

[0035] (4) The recombinant baculovirus rMG-F obtained in step (3) is inoculated into HF cells for mass culture, and the culture supernatant is collected by centrifugation to obtain the MGepitopes recombinant protein.

[0036] (5) The recombinant protein of step (4) is purified, an adjuvant is added, emulsified, and finally mixed to prepare a genetically engineered fusion epitope subunit vaccine for preventing Mycoplasma gallisepticum.

[0037] In one embodiment, the adjuvant includes, but is not limited to, aluminum salt adjuvant, liposome adjuvant, water-in-oil adjuvant, water-in-oil adjuvant, nanoparticle adjuvant, and saponin adjuvant.

[0038] In one embodiment, the adjuvant is a mineral oil adjuvant.

[0039] In one embodiment, the total content of the multi-epitope fusion antigen MGepitopes is 50-150 μg / mL.

[0040] The beneficial effects of the present invention are:

[0041] 1. The present invention fuses and expresses the B cell and T cell epitopes of multiple key antigens of Mycoplasma gallisepticum to obtain a genetic engineering fusion epitope subunit vaccine for preventing Mycoplasma gallisepticum. It has a good immune effect and a small immune dose. Only one immunization can achieve a protection rate of 90-100%, effectively preventing diseases related to Mycoplasma gallisepticum infection or diseases related to Mycoplasma gallisepticum infection, while also reducing the labor cost and vaccine cost of chicken farms.

[0042] 2. The preparation method of the Mycoplasma gallisepticum genetic engineering fusion epitope subunit vaccine provided by the present invention is simple, can prepare a large amount of antigen protein of Mycoplasma gallisepticum disease, is time-saving, has a high expression amount, greatly reduces the production cost, and is conducive to large-scale production. BRIEF DESCRIPTION OF THE DRAWINGS

[0043] Figure 1 The recombinant baculovirus expression product was detected by SDS-PAGE; 1: MGepitopes; 2: blank control;. DETAILED DESCRIPTION

[0044] The present invention is further described below in conjunction with the accompanying drawings and specific examples, but the examples do not limit the present invention in any form. Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art.

[0045] Unless otherwise specified, the reagents and materials used in the following examples are commercially available or can be prepared by known methods.

[0046] The experimental materials involved in the following examples

[0047] Mycoplasma gallisepticum CR strain was purchased from the Chinese Institute of Veterinary Drug Control.

[0048] The commercial plasmid pFastBac I and Escherichia coli DH10Bac competent cells were purchased from Thermo Company.

[0049] Example 1: Construction of recombinant baculovirus

[0050] 1. Construction of transfer vector: The fusion epitope antigen protein MGepitopes (SEQ ID NO.1) of Mycoplasma gallisepticum was commissioned to Anhui General Biotechnology for gene synthesis and connected to the commercial vector pFastBac I to obtain the transfer vector MG-F.

[0051] 2. Construction of recombinant baculovirus: The transfer vector MG-F synthesized in step 1 was respectively transformed into E. coli DH10Bac competent cells, and positive clones were selected for PCR identification using M13 primers.

[0052] M13-F: TGTAAAACGACGGCCAGT;

[0053] M13-R: CAGGAAACAGCTATGAC.

[0054] The PCR reaction system was (total volume 25 μL): 0.5 μL DNA template, 0.5 μL each of M13-F and M13-R, 12.5 μL DNA polymerase and 11 μL sterile water.

[0055] PCR reaction conditions were: 93°C, 5 min; 94°C 30 s, 55°C 45 s, 72°C 5 min, 30 cycles; 72°C 10 min.

[0056] The PCR product was subjected to 1% agarose gel electrophoresis, and the results showed that a specific band of about 3000-5000 bp was successfully amplified, which was consistent with the expected size. The positive recombinant bacmid was named rBacmid-MG-F.

[0057] 3. Transfection of recombinant bacmid into sf9 cells: The positive recombinant bacmid in step 2 is transfected into insect cells sf9 by liposome transfection. The specific operation method is carried out according to the instruction manual of Cellfectin transfection reagent of Thermo Fisher Scientific (China) Co., Ltd. to obtain the F1 generation recombinant baculovirus rMG-F.

[0058] Example 2: Preparation of recombinant protein

[0059] 1. Amplification of recombinant baculovirus: The f1 generation recombinant baculovirus rMG-F obtained in Example 1 was inoculated into insect cells sf9, cultured at 27° C. for 4 days, the culture was collected, and the supernatant was obtained by centrifugation to obtain the f2 generation recombinant baculovirus;

[0060] 2. Identification of expressed proteins:

[0061] (1) The f2 generation recombinant baculovirus rMG-F obtained in step 1 was inoculated into insect cells sf9 at an MOI of 5 to 10, cultured at 27° C. for 4 days, the culture was collected, and the supernatant was obtained by centrifugation to obtain the recombinant protein MGepitopes;

[0062] (2) SDS-PAGE identification: The supernatant obtained in step (2) was subjected to SDS-PAGE electrophoresis; after electrophoresis, it was found that the MGepitopes sample band was 43 kDa after staining and decolorization. The band size of the electrophoresis results was consistent with the theoretical molecular weight of the target protein, proving that the protein was successfully expressed ( Figure 1 ).

[0063] 3. Mass expression of recombinant protein MGepitopes: The correctly identified recombinant baculovirus rMG-F was inoculated into HF cells at an MOI of 1 to 10 for mass culture, and the culture supernatant was collected by centrifugation to obtain a large amount of recombinant protein MGepitopes.

[0064] 4. Protein purification: The protein was purified by conventional Ni affinity chromatography. For specific experimental operations, please refer to the Ni-NTA Purose 6 Fast Flow filler instructions of Qianchun Biotechnology Co., Ltd.

[0065] Example 3: Vaccine preparation

[0066] 1. Inactivation: Add the MGepitopes recombinant protein prepared in Example 2 into an inactivation tank, add the inactivator BEI at a final concentration of 0.2% to 0.5%, and inactivate at 37° C. for 24 h.

[0067] 2. Semi-finished product inspection

[0068] (1) Sterility test: Sterility test shall be carried out in accordance with the appendix of the current Pharmacopoeia of the People's Republic of China.

[0069] (2) Protein content determination: The protein content was determined by the BCA method.

[0070] (3) Inactivation test: The inactivated recombinant proteins were inoculated into insect cells sf9 and cultured at 27°C for 72 hours. If no lesions were observed, the inactivation test was considered qualified.

[0071] 3. Vaccine Vaccine composition preparation:

[0072] The semi-finished protein antigen that has passed the inspection is used for vaccine preparation (the liquid components in the following preparation are calculated by volume ratio).

[0073] (1) Preparation of oil phase: Take 95 parts of veterinary white oil and 1 part of aluminum stearate, place them in an oil phase preparation tank and heat them to 80°C, then add 5 parts of Siben-80 and maintain the temperature until it reaches 115°C. Cool and set aside.

[0074] (2) Preparation of aqueous phase: dilute the recombinant protein inactivated in each step 1 with physiological saline to an appropriate concentration (50 μg / ml, 100 μg / ml, 150 μg / ml), and mix them in an appropriate ratio. Take 5 parts of sterilized Tween-80 and add them to the liquid preparation tank, and add 95 parts of the protein solution for seedling preparation at the same time, and stir for 20 to 30 minutes to completely dissolve the Tween-80.

[0075] (3) Emulsification: Put 2 portions of the oil phase into a high-speed shearing machine, start the motor to slowly rotate and stir, and slowly add 1 portion of the water phase, emulsify at 10,000 rpm for 5 minutes. After emulsification, take 10 mL and centrifuge at 3,000 rpm for 15 minutes. The water phase precipitated at the bottom of the tube should not exceed 0.5 mL.

[0076] Example 4: Finished vaccine product inspection

[0077] 1. Properties

[0078] Appearance: The vaccine should be a milky white emulsion, free of impurities and the outer packaging should be qualified;

[0079] Dosage form: Oil-in-water type. Take a clean pipette, draw a small amount of vaccine and drop it into cold water. Except for the first drop, it should not spread.

[0080] Stability: Pipette 10mL of vaccine into a centrifuge tube and centrifuge at 3000rpm for 15min. The amount of water precipitated at the bottom of the tube should not exceed 0.5mL.

[0081] Viscosity: It should comply with the regulations in the appendix of the current "Pharmacopoeia of Veterinary Medicine of the People's Republic of China".

[0082] 2. Filling quantity inspection: It shall be carried out in accordance with the appendix of the current "Pharmacopoeia of Veterinary Medicine of the People's Republic of China" and shall comply with the regulations.

[0083] 3. Sterility test: It shall be carried out in accordance with the appendix of the current "Pharmacopoeia of Veterinary Medicine of the People's Republic of China" and shall comply with the regulations.

[0084] 4. Safety inspection:

[0085] There are three batches of genetically engineered fusion epitope subunit vaccine of Mycoplasma gallisepticum, namely rMG-001P (protein content 50μg / ml), rMG-002P (protein content 100μg / ml), and rMG-003P (protein content 150μg / ml).

[0086] Thirty healthy SPF chickens aged 14 days were selected, and 1.0 mL of the vaccine was injected subcutaneously in the neck of each chicken. The experimental animals were observed for 14 days for obvious local or systemic adverse reactions. The results showed that the experimental animals had no adverse reactions after the vaccine injection (such as lying down, loss of appetite, no scabs or swelling at the injection site, and no vaccine residue at the injection site after autopsy).

[0087] 5. Effectiveness test:

[0088] 5.1 Grouping and challenge: 40 healthy SPF chickens aged 14 days were randomly divided into 4 groups, with 10 in each group. Groups A, B, and C were immunized with different batches of vaccines, and 0.2 mL of vaccine was injected subcutaneously in the neck of each chicken. Group D was the control. 21 days after immunization, the virulent strain CR of Mycoplasma gallisepticum was used for the challenge experiment. After 14 days of observation, the experimental animals were dissected to observe the air sac lesions.

[0089] 5.2 Efficacy test results: 40 healthy SPF chickens aged 14 days were randomly divided into 4 groups, with 10 chickens in each group. Groups A, B, and C were immunized with different batches of vaccines, and 0.2 mL of vaccine was injected subcutaneously in the neck of each chicken. Group D was the control. 21 days after immunization, the CR strain of Mycoplasma gallisepticum was used for the challenge experiment. The immune protection rate of the three batches of vaccines was not less than 9 / 10, and the control disease rate was 10 / 10. See the table below for details.

[0090] Table 1 Results of efficacy test of Mycoplasma gallisepticum genetically engineered fusion epitope subunit vaccine

[0091]

[0092] Although the present invention has been disclosed as above in the form of a preferred embodiment, it is not intended to limit the present invention. Anyone familiar with this technology can make various changes and modifications without departing from the spirit and scope of the present invention. Therefore, the scope of protection of the present invention should be based on the definition of the claims.

Claims

1. A multi-epitope fusion antigen MGepitopes, characterized in that: The amino acid sequence of the multi-epitope fusion antigen MGepitopes is shown in SEQ ID NO.

1.

2. A gene encoding the multi-epitope fusion antigen MGepitopes according to claim 1.

3. A biomaterial expressing the multi-epitope fusion antigen MGepitopes according to claim 1, characterized in that: The biological material is any one of the following (1) to (3): (1) A vector expressing the coding gene of the multi-epitope fusion antigen MGepitopes; (2) a host cell containing a gene encoding the multi-epitope fusion antigen MGepitopes or containing the vector described in (1); (3) A recombinant virus containing a gene encoding the multi-epitope fusion antigen MGepitopes or containing the vector described in (1).

4. A composition, characterized in that The composition comprises the multi-epitope fusion antigen MGepitopes according to claim 1 or the gene according to claim 2 or the biological material according to claim 3.

5. A genetically engineered fusion epitope subunit vaccine for preventing Mycoplasma gallisepticum, characterized in that: The vaccine contains the multi-epitope fusion antigen MGepitopes according to claim 1.

6. The subunit vaccine according to claim 5, characterized in that The total content of the multi-epitope fusion antigen MGepitopes in the subunit vaccine is 50-150 μg / mL.

7. Use of the multi-epitope fusion antigen MGepitopes according to claim 1, the gene according to claim 2, the biological material according to claim 3, or the composition according to claim 4 in the preparation of a medicament for preventing and / or controlling Mycoplasma gallisepticum infection or Mycoplasma gallisepticum disease.

8. The use according to claim 7, characterized in that: The medicaments include subunit vaccines.

9. Use of the multi-epitope fusion antigen MGepitopes according to claim 1, the gene according to claim 2, the biological material according to claim 3, or the composition according to claim 4 in the preparation of Mycoplasma gallisepticum antibodies or Mycoplasma gallisepticum serum.

Citation Information

Patent Citations

  • Novel gene engineering subunit vaccine for mycoplasma gallisepticum

    CN109999191A

  • Mycoplasma gallisepticum multi-epitope fusion protein pMG-and application thereof

    CN112159479A